News Image

ProMIS Neurosciences Announces Publication on Novel Target for ALS

Provided By GlobeNewswire

Last update: Dec 20, 2023

Study results published in Acta Neuropathologica Communications support targeting of RACK1 as a potential therapeutic approach for Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Lobar Degeneration (FTLD).

Read more at globenewswire.com

PROMIS NEUROSCIENCES INC

NASDAQ:PMN (5/1/2025, 9:25:12 PM)

0.65

+0.03 (+4.86%)



Find more stocks in the Stock Screener

Follow ChartMill for more